Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

The Business Cocktail

The Business Cocktail

Mar 21, 2019

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million

GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review
voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug
Administration programme to accelerate speedy recovery of rare disease. GW received the voucher
when FDA approved its cannabinoid medicine Epidiolex for treating seizures.

BioMed Realty acquires Emeryville Center for Innovation

BioMed Realty-a blackstone portfolio company has acquired Emeryville Center for Innovation for USD
135 million. This campus acquisition of around 250,000 square foot, six-story life science office building
will help BioMed to dominate the market of Life Sciences in San Francisco.

Merck, Iktos to explore AI for drug discovery

Merck, a leading science and technology company has decided to use its generative modelling artificial
intelligence (AI) technology to facilitate the rapid and cost-effective discovery and design of promising
new compounds in collaboration with Iktos’ AI technology.

Merck, and GenScript for Cell and Gene Therapy in China

Merck among the only few to industrialize the process of making viral vectors has now announced its
decision to commercialize the Cell and Gene therapy in collaboration with GenScript- a China biotech
company. Merck will extend its support in processing products, services and staff training to GenScript
to accelerate the manufacturing of plasmids and viral vectors.

Downloads

Article in PDF

Recent Articles
  1. Amgen to Acquire Horizon Therapeutics; Sanofi and Teva Announce Collaboration; Boehringer Obesity...
  2. Tecelra by Adaptimmune: First FDA-Approved Engineered Cell Therapy for Solid Tumors; GSK’s ...
  3. FDA approves Ofev for interstitial lung disease
  4. Smith+Nephew’s Hip Arthroplasty System; Mammotome Launched the HydroMARK Plus Breast Biopsy Site ...
  5. Cost ineffective Orphan Drugs limit the access
pharma-news-for-abbvie-gsk-novartis
Notizia - Recent Pharma, Healthcare and Biotech Happenings

AbbVie Reveals Phase III TEMPO-2 Trial Positive Topline Results; FDA Accepts GSK’s NUCALA Submission in COPD; Novartis Boosts Huntington’s Disease Development Program with PTC518 In-Licensing; Chimerix to File for Accelerated FDA Approval of Dordaviprone for H3 K27M-Mutant Diffuse Glioma; MeiraGTx Receives FDA RMAT Designation for AAV2-hAQP1 in Grade 2/3 Radiation-Induced Xerostomia Treatment

pharma-news-for-applied-therapeutics-alnylam-rigel
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses
Articles

Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses

AI
Artificial technology
Biohaven
BioMed Realty
Blackstone
cannabinoid
cell therapy
China
drug discovery
Emeryville Center of Innovation
Epidiolex
FDA
Gene therapy
GenScript
GW Pharmaceuticals
Iktos
Merck
Plasmid
PRV
Rare Disease
San Francisco
Seizures
USD
viral vector
loader